Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Holly Finertie

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 15, 2025
GLP-1RA comparative effectiveness against dementia onset relative to other antidiabetic medications in a large, multi-site cohort of patients with type 2 diabetesNerissa Nance, Paola Gilsanz, Andrew J Karter, et al.
Lancet Regional Health. Americas|May 15, 2024
Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetesLuis A Rodriguez, Holly Finertie, Romain S Neugebauer, et al.
Diabetes, Obesity & Metabolism|January 2, 2026
Comparative safety of glucose-lowering medications on depression in adults with type 2 diabetesStephanie A Hooker, Romain S Neugebauer, Julie A Schmittdiel, et al.
JAMA Network Open|October 15, 2025
Glucose-Lowering Medication Classes and Cardiovascular Outcomes in Patients With Type 2 DiabetesRomain Neugebauer, Jaejin An, Sarah Krahe Dombrowski, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 15, 2025
GLP-1RA comparative effectiveness against dementia onset relative to other antidiabetic medications in a large, multi-site cohort of patients with type 2 diabetesNerissa Nance, Paola Gilsanz, Andrew J Karter, et al.
Lancet Regional Health. Americas|May 15, 2024
Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetesLuis A Rodriguez, Holly Finertie, Romain S Neugebauer, et al.
Diabetes, Obesity & Metabolism|January 2, 2026
Comparative safety of glucose-lowering medications on depression in adults with type 2 diabetesStephanie A Hooker, Romain S Neugebauer, Julie A Schmittdiel, et al.
JAMA Network Open|October 15, 2025
Glucose-Lowering Medication Classes and Cardiovascular Outcomes in Patients With Type 2 DiabetesRomain Neugebauer, Jaejin An, Sarah Krahe Dombrowski, et al.
Pageof 2